drugset / Trial / NCT05604560
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable pancreatic adenocarcinoma.
Timeline
- Start
- 2023-11-08
- Primary completion
- 2027-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SX-682 | Small molecule | 200 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |